#Australia

ALS Limited: A High-Quality Compounder with a Cyclical Sidecar

ALS Limited is a global laboratory-testing group that earns most of its revenue from Life Sciences yet a disproportionate share of margin from minerals-related Commodities testing, so a diversified TIC provider still trades, at key moments, like a high-quality miner's service proxy. FY26 delivered record revenue of A$3.32 billion and an 18.0% underlying EBIT margin, hitting the FY27 strategic targets a year early, but at A$23.36 the stock trades near 37 times trailing EPS with the margin of safety put at zero. Rating Hold: a strong dual-engine testing franchise whose price already discounts commodities strength, acquisition repair and future hub productivity, leaving little room for disappointment.